BCL9L and colorectal carcinoma: Conversely, in colorectal cancer (CRC), Subramanian et al. reported that miR-29b antagonized the transactivation of β-catenin target genes by downregulating the co-activators of β-catenin such as the TCF7L2, BCL9L, and Snail1 [45].